Prion removal capacity of plasma protein manufacturing processes
Authors:
- 17 December 2012
- journal article
- research article
- Published by Wiley in Transfusion
- Vol. 53 (9) , 1894-1905
Abstract
Background: The variant Creutzfeldt‐Jakob disease incidence peaked a decade ago and has since declined. Based on epidemiologic evidence, the causative agent, pathogenic prion, has not constituted a tangible contamination threat to large‐scale manufacturing of human plasma‐derived proteins. Nonetheless, manufacturers have studied the prion removal capabilities of various manufacturing steps to better understand product safety. Collectively analyzing the results could reveal experimental reproducibility and detect trends and mechanisms driving prion removal.Study Design and Methods: Plasma Protein Therapeutics Association member companies collected more than 200 prion removal studies on plasma protein manufacturing steps, including precipitation, adsorption, chromatography, and filtration, as well as combined steps. The studies used a range of model spiking agents and bench‐scale process replicas. The results were grouped based on key manufacturing variables to identify factors impacting removal. The log reduction values of a group are presented for comparison.Results: Overall prion removal capacities evaluated by independent groups were in good agreement. The removal capacity evaluated using biochemical assays was consistent with prion infectivity removal measured by animal bioassays. Similar reduction values were observed for a given step using various spiking agents, except highly purified prion protein in some circumstances. Comparison between combined and single‐step studies revealed complementary or overlapping removal mechanisms. Steps with high removal capacities represent the conditions where the physiochemical differences between prions and therapeutic proteins are most significant.Conclusion: The results support the intrinsic ability of certain plasma protein manufacturing steps to remove prions in case of an unlikely contamination, providing a safeguard to products.Keywords
This publication has 41 references indexed in Scilit:
- All Clinically-Relevant Blood Components Transmit Prion Disease following a Single Blood Transfusion: A Sheep Model of vCJDPLOS ONE, 2011
- Capacity of the manufacturing process of Flebogamma® DIF, a new human high purity intravenous immunoglobulin, to remove a TSE model-agentBiologicals, 2010
- Elimination capacity of a TSE‐model agent in the manufacturing process of Alphanate®/Fanhdi®, a human factor VIII/VWF complex concentrateHaemophilia, 2009
- An update on the assessment and management of the risk of transmission of variant Creutzfeldt‐Jakob disease by blood and plasma productsBritish Journal of Haematology, 2008
- Investigations of prion and virus safety of a new liquid IVIG productBiologicals, 2008
- Effectiveness of leucoreduction for removal of infectivity of transmissible spongiform encephalopathies from bloodThe Lancet, 2004
- Partitioning of TSE infectivity during ethanol fractionation of human plasmaBiologicals, 2004
- Solvent-dependent precipitation of prion proteinBiochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 2002
- Ultrastructural Studies on Scrapie Prion Protein Crystals Obtained from Reverse Micellar SolutionsBiophysical Journal, 1999
- Preparation and Properties of Serum and Plasma Proteins. IV. A System for the Separation into Fractions of the Protein and Lipoprotein Components of Biological Tissues and Fluids1a,b,c,dJournal of the American Chemical Society, 1946